Skip to content

Trial Summary

This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety, tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).

Acronym:

ZN-d5-001

ACTRN/NCT /ethics:

NCT04500587

Scientific title:

Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia

Sponsor / Cooperative group:

K-Group Alpha, Inc.

Trial & Patient Characteristics

Cancer TypeNon-Hodgkin Lymphoma; Acute Myeloid Leukemia
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer Stage-
Anticipated Start Date2020-10-13
Anticipated End Date2023-05-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Akash Kalro
Recruitment StatusNot Yet Recruiting